Structure and function of P2Y2 nucleotide receptors in cystic fibrosis (CF) epithelium

1997 ◽  
Vol 30 (3) ◽  
pp. 295
Author(s):  
G.A. Weisman ◽  
R.C. Garrad ◽  
L.J. Erb ◽  
J.T. Turner ◽  
L.L. Clarke ◽  
...  
1999 ◽  
Vol 79 (1) ◽  
pp. S23-S45 ◽  
Author(s):  
DAVID N. SHEPPARD ◽  
MICHAEL J. WELSH

Sheppard, David N., and Michael J. Welsh. Structure and Function of the CFTR Chloride Channel. Physiol. Rev. 79 , Suppl.: S23–S45, 1999. — The cystic fibrosis transmembrane conductance regulator (CFTR) is a unique member of the ABC transporter family that forms a novel Cl− channel. It is located predominantly in the apical membrane of epithelia where it mediates transepithelial salt and liquid movement. Dysfunction of CFTR causes the genetic disease cystic fibrosis. The CFTR is composed of five domains: two membrane-spanning domains (MSDs), two nucleotide-binding domains (NBDs), and a regulatory (R) domain. Here we review the structure and function of this unique channel, with a focus on how the various domains contribute to channel function. The MSDs form the channel pore, phosphorylation of the R domain determines channel activity, and ATP hydrolysis by the NBDs controls channel gating. Current knowledge of CFTR structure and function may help us understand better its mechanism of action, its role in electrolyte transport, its dysfunction in cystic fibrosis, and its relationship to other ABC transporters.


2015 ◽  
Vol 22 (5) ◽  
pp. 257-260 ◽  
Author(s):  
Bradley S Quon ◽  
Pearce G Wilcox

The gene responsible for cystic fibrosis (CF) was discovered 25 years ago. This breakthrough has enabled a sophisticated understanding of how various mutations lead to specific alterations in the structure and function of the CF transmembrane regulator (CFTR) protein. Until recently, all therapies in CF were focused on ameliorating the downstream consequences of CFTR dysfunction. High-throughput drug screening approaches have yielded compounds that can modify CFTR structure and function, thus targeting the basic defect in CF. The present article describes theCFTRmutational classes, reviews mutation-specific therapies currently in late-phase clinical development, and highlights research opportunities and challenges with personalized medicine in CF.


2010 ◽  
Author(s):  
Raghav K. Chhetri ◽  
Jerome Carpenter ◽  
Richard Superfine ◽  
Scott H. Randell ◽  
Amy L. Oldenburg

Author(s):  
Virginia Mirra ◽  
Marco Maglione ◽  
Silvia Montella ◽  
Francesca Santamaria ◽  
Carmine Mollica ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document